Position in EVO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$41,277
New position
Shares Held
14,742
first reported quarter
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#14
of 34 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026CAPTRUST FINANCIAL ADVISORS holds $43,412,538 across 29 Drug Manufacturers - Specialty & Generic names. EVO ranks #28 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
121,151 | $8,705,910 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
45,360 | $7,644,974 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
9,855 | $5,339,734 | |
| 4 | VTRS |
Viatris Inc
|
197,717 | $3,139,745 | |
| 5 | HLN |
Haleon plc
|
263,202 | $2,455,674 | |
| 6 | HROW |
Harrow, Inc.
|
56,414 | $2,395,902 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
143,998 | $2,308,287 | |
| 8 | ALKS |
Alkermes plc.
|
42,278 | $2,215,367 |
All Filings in EVO
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $41,277 | 14,742 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||